Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on BYOTROL PLC. We currently have 20 research reports from 3 professional analysts.
|06Feb17 07:00||RNS||Director Dealing|
|01Feb17 07:00||RNS||Board changes and issue of options|
|13Dec16 07:00||RNS||Interim Results|
|07Dec16 12:29||RNS||Notice of Interim Results|
|14Oct16 07:00||RNS||Grant of Options and Director Shareholdings|
|12Oct16 07:00||RNS||Transfer of Convertible Loan Notes|
Frequency of research reports
Research reports on
13 Dec 16
Byotrol* (BYOT): Interim results hide true FY picture (CORP) | Seeing Machines* (SEE): Fovio strategy shift opens equity opportunity (CORP) | Utilitywise* (UTW): Capitalising on the water opportunity (CORP) | OptiBiotix* (OPTI): Joint product agreement with multinational (CORP) | Vectura (VEC): Withdrawal of forecasts (U/R) | AorTech International* (AOR): Termination of coverage
Interim results hide true FY picture
13 Dec 16
Byotrol released interim results for the six months to 30 September. Despite LBITDA of £0.51m (£0.32m), we expect full-year adjusted EBITDA of £0.1m as a result of contractual payments in excess of £1m in H2. Equally significant is that (i) the company has confirmed that it will file its consumer product formulation with the EPA in the US prior to Christmas; (ii) it is in discussions with a number of global FMCGs over Actizone technology (joint Solvay agreement); and (iii) Kyorin has launched its non-alcohol hand sanitiser formulation into the Japanese hospital market. We make small changes to our full-year forecasts and leave unchanged our price target of 6.9p, which is based on a five-year discounted DCF valuation.
29 Nov 16
The prospect of Hilary Clinton creating an oversight panel with the power to impose a set of harsh enforcement rules to control aggressive pricing of pharmaceuticals in the US fell away with the election of Trump, leading to a 16% bounce in the NASDAQ Biotech index and an 8% increase in the US Pharma & Biotech index, some of which has already been given back.
N+1 Singer - N1S Trend spotting - Strategy update
08 Mar 17
In this new product we present some strategy theme updates arising out of our latest analysis of macro trends and economic data and our innovative Quant work. We also look at upcoming events and suggest topping up on some of our Best Ideas for 2017.
Small Cap Breakfast
03 Mar 17
Venn Life Sciences*( VENN . L) | MediaZest* (MDZ.L) | Legendary Investments (LEG.L) | AFH Financial (AFH.L) | Intercede Group (IGP.L) | Gear4Music Holdings (G4M.L) | Trakm8 Holdings (TRAK.L) | Kodal Minerals (KOD.L) | Applied Graphene Materials (AGM.L) | Velocys (VLS.L)
14 Mar 17
Zotefoams finals present a mixed picture. After a slow first half, when revenues grew 2%, stronger growth in H2 left overall revenues up 7% to £57.4m, helped by a strong FX tailwind. On a constant FX basis, revenues were 3% lower, with declines in Polyolefin foams and MuCell more than offsetting growth in HPP.